Company: CORT
Filing Date: 2025-11-04
Form Type: 10-Q
Source: 0001628280-25-048841
Chunk: 14

Company: CORCEPT THERAPEUTICS INC
Filing Date: 2025-11-04
Form: 10-Q
Item: Part I, Item 1
Chunk 14
---
 at the current market price, shares equal in value to the associated exercise price and tax withholding obligations. During the three and nine months ended September 30, 2025, we purchased 0.1 million and 0.6 million shares, respectively, in connection with option net exercises and paid $4.0 million and $24.6 million, respectively, to satisfy associated tax withholding obligations.During the three and nine months ended September 30, 2024, we issued 1.0 million and 1.8 million, respectively, shares of our common stock upon the exercise of stock options. Some option holders exercised their options on a “net exercise” basis, pursuant to which they surrendered to us, and we purchased from them at the then current market price shares equal in value to the associated exercise price and tax withholding obligations. During the three and nine months ended September 30, 2024, we 

14

purchased 0.5 million and 0.8 million shares, respectively, in connection with option net exercises and paid $10.5 million and $12.2 million, respectively, to satisfy associated tax withholding obligations.Restricted Stock Awards (“RSAs”) and Restricted Stock Units (“RSUs”)During the three and nine months ended September 30, 2025, we granted employees 0.2 million and 1.0 million RSAs, respectively, with a weighted-average grant date fair value of $69.96 and $65.99 per share, respectively. During the three and nine months ended September 30, 2025, we paid $4.1 million and $11.8 million, respectively, to satisfy associated tax withholding obligations in connection with RSA and RSU vesting.During the three and nine months ended September 30, 2024, we granted employees 0.2 million and 0.8 million RSAs, respectively, with a weighted-average grant date fair value of $34.58 and $27.07 per share, respectively. During the three and nine months ended September 30, 2024, we paid $1.1 million and $3.1 million, respectively, to satisfy associated tax withholding obligations in connection with RSA and RSU vesting. RSAs include voting and dividend rights and are therefore “participating” shares for the purpose of calculating basic and diluted net income per share. See “Note 7” below.Employee Stock Purchase Plan